FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending May 2009
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification
of Transactions of Directors, Persons Discharging Managerial Responsibility or
Connected Persons
The Administrators of the
SmithKline Beecham Mid-Term Incentive Plan notified the Company and the
under-mentioned persons on 11 May 2009 of an increase in
their interests in Ordinary share ADRs at a price of $29.58 per
ADR following the re-investment of the dividend paid to shareholders
on 9 April 2009.
|
Mr E J Gray |
20.36 |
|
Mr D J Phelan |
617.29 |
This notification relates
to transactions notified in accordance with Disclosure and
Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
11 May 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorised.
GlaxoSmithKline plc
(Registrant)
Date: May 11 2009
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc